Загрузка компании
Доли выручки — это оценки за 2025, а не цифры из поданной отчётности.
Xywav
A low-sodium liquid medicine for cataplexy and excessive daytime sleepiness in people with narcolepsy, and for idiopathic hypersomnia in adults.
Epidiolex
A purified cannabidiol liquid medicine used to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.
Ziihera
An antibody medicine for certain cancers with high levels of human epidermal growth factor receptor 2 (HER2), including bile duct cancer and, in the United States, stomach and related cancers.
Modeyso
A medicine for diffuse midline glioma with an H3 K27M mutation that has progressed after earlier treatment; it is also approved for this condition in Japan.
Zepzelca
A cancer medicine used with atezolizumab as maintenance treatment for some adults with extensive-stage small-cell lung cancer.
Rylaze
An injectable medicine used as part of chemotherapy for acute lymphoblastic leukemia or lymphoblastic lymphoma when a patient is hypersensitive to an E. coli-derived medicine.
Полная финансовая отчётность →
Jazz develops and sells prescription medicines, focusing on rare sleep disorders, epilepsy and cancers. Its largest products include Xywav for narcolepsy and idiopathic hypersomnia and Epidiolex for seizures linked to certain rare conditions. It also sells cancer medicines and runs clinical trials to test new medicines and uses for existing ones. At September 30, 2026, about 17,550 patients were taking Xywav (high confidence).
Построено по собственной отчётности Jazz Pharmaceuticals plc, поданной в Комиссию по ценным бумагам и биржам США (SEC). Цифры — как отчиталась компания, история на акцию пересчитана на сегодняшнюю базу. Это описание бизнеса — не инвестиционная рекомендация и не совет что-либо покупать или продавать.
Jazz sells low-sodium oxybate medicine for narcolepsy and idiopathic hypersomnia, plus epilepsy and cancer drugs to patients through pharmacies and hospitals.
Прогноз компании: выручка от 4,8B $ до 4,9B $ за 2026 финансовый год — на 12,8 % больше, чем годом ранее
Just reported
From Jazz Pharmaceuticals's results release of 2 ноября 2026 г.; its quarterly report has since been filed.
Actual
1,24B $
+10 % y/y
+2,9 % q/q
Guided
—
No guide given
Actual
-7,48 $
Guided
—
No guide given
Actual
-413,4M $
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Jazz Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A
Полоса под ценой показывает оценку на каждую дату — только по отчётам, которые к тому моменту уже были опубликованы.
Показано 2 из 41 кварталов истории оценок компании Jazz Pharmaceuticals plc. Остальные 39 уходят к ноябрь 2016 г..
